Umecrine Cognition's Phase 1b/2a Trial of Golexanolone for PBC Faces Temporary Delay Due to Manufacturing Issues
Key Insights
Umecrine Cognition (search) has announced a temporary delay in their Phase 1b/2a clinical trial of golexanolone for Primary Biliary Cholangitis (search) due to technical issues in capsule production.
Golexanolone is being developed as a novel GABAA receptor-modulating steroid antagonist (search) targeting cognitive impairment and fatigue in PBC (search) patients, with no patient safety concerns reported despite the delay.
The company, which is 73% owned by Karolinska Development AB (search), is working with suppliers to resolve the manufacturing problems and resume patient recruitment in the randomized, double-blind, placebo-controlled study.
Umecrine Cognition (search) announced today that its ongoing Phase 1b/2a clinical trial evaluating golexanolone in Primary Biliary Cholangitis (search) (PBC (search)) patients is experiencing a temporary delay due to technical issues in the production of capsules used in the study. The company emphasized that no patient safety concerns have been identified, and they are working closely with suppliers to resolve the manufacturing problems.
"We regret that the supply issue will temporarily impact the pace of patient recruitment in the ongoing clinical study of golexanolone, but we are confident that the manufacturing problem can be diligently resolved," said Anders Karlsson, CEO of Umecrine Cognition (search).
Drug Candidate and Clinical Program
Golexanolone represents a novel class of drugs targeting impaired cognitive function and central fatigue in patients with PBC (search). The compound acts as a GABAA receptor-modulating steroid antagonist (search), designed to normalize brain signaling that becomes disrupted due to chronic neuroinflammation.
The current clinical evaluation consists of a two-part Phase 1b/2a study. The ongoing second part (part B) aims to further document golexanolone's pharmacological profile while evaluating its efficacy on cognitive symptoms and fatigue in PBC (search) patients. The trial is designed as a randomized, double-blind, placebo-controlled study in patients who experience clinically significant fatigue and cognitive symptoms.
Clinical Significance and Unmet Need
Primary Biliary Cholangitis (search) is a chronic autoimmune liver disease that primarily affects women and can lead to liver failure if untreated. Beyond the direct hepatic impact, PBC (search) patients frequently experience debilitating cognitive dysfunction and fatigue that significantly impair quality of life, with limited effective treatment options currently available.
Previous clinical results from an internationally acclaimed Phase 2 study indicated that golexanolone normalized brain signaling and improved cognition and alertness in patients with hepatic encephalopathy (search), suggesting potential benefit in PBC (search)-related cognitive symptoms.
Broader Development Program
Based on promising preclinical data, Umecrine Cognition (search) is also considering expanding golexanolone's development into Parkinson's disease (search), highlighting the potential broader applications of the drug's mechanism in addressing neuroinflammation-related cognitive impairment.
The company's approach targets chronic neuroinflammation, a devastating brain distortion that can occur as a result of various underlying conditions, including liver diseases and neurodegenerative disorders.
Corporate Background
Umecrine Cognition (search) is a portfolio company of Karolinska Development AB (search), which holds a 73% ownership stake. Karolinska Development (Nasdaq Stockholm: KDEV) focuses on identifying and developing breakthrough medical innovations in the Nordic region.
The company is developing a completely new class of drugs for treating central nervous system symptoms related to chronic neuroinflammation, with golexanolone as its most advanced candidate.
Despite the current manufacturing challenges, the company remains committed to advancing golexanolone through clinical development to address significant unmet medical needs in PBC (search) and potentially other neuroinflammatory conditions.